Key Takeaways TEM signed a $200M three-way deal with AZN and Pathos to build a multimodal oncology foundation model. The partnership lifts TEM's total remaining contract value to over $1B as of April 2025. TEM also expanded ties with ILMN to advance molecular profiling across all major disease areas.ForTempus AI (TEM) , expanding partnerships with existing customers across each of its product lines is key to its growth. In April 2025, the AI-driven precision medicine company extended its collaboration wit ...

Key Takeaways CALM's Q3 shell egg sales hit 331.4M dozen, up 10.2% year over year on strong seasonal demand. Year-to-date volume reached 971.2M dozen eggs, marking a 17% increase over the prior-year period. Capacity expansion and biosecurity efforts are expected to support continued production growth in 2025.Cal-Maine Foods, Inc. (CALM) , the largest producer and distributor of fresh shell eggs in the United States, sold a record 331.4 million dozen shell eggs in the third quarter of fiscal 2025 (ended Ma ...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (“IPO” or the “Offering”), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the fir ...

LOS ANGELES, June 13, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 22, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) securities between October 31, 2024 to April 30, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR ORGANON INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YO ...

Key Takeaways PATH trades at a 4.37x forward P/S, below 5.68x of the industry average, suggesting relative undervaluation. Strong recurring revenues, global expansion and AI integrations support PATH's enterprise momentum. PATH's valuation trails peers like NOW and PEGA, despite faster growth and a focused automation strategy.UiPath Inc. (PATH) appears attractively valued compared with its industry peers based on the forward 12-month price-to-sales (P/S) ratio. Currently trading at 4.37x, PATH’s valuation ...

CHICAGO, June 13, 2025 /PRNewswire/ -- McDonald's USA, LLC and Entertainment Studios Network/The Weather Group today announced an agreement to settle pending litigation between them. The parties reached a confidential commercial agreement whereby McDonald's will continue to purchase advertising from ESN in a manner that aligns with its advertising strategy and commercial objectives and ESN will dismiss its lawsuit against McDonald's in the United States District Court for the Central District of California. ...

Biotechnology research firm Thermo Fisher Scientific is reportedly looking to sell part of its diagnostics business amid industrywide concerns about federal cutbacks in spending on research.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no add ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

My recent coverage of UroGen Pharma (NASDAQ: URGN ) was the prospective risk-taker's manifesto on a very shaky FDA decision. Now that this thesis has worked out, the "predictions" laid out in that article appear to be nearlyI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the p ...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Compass Diversified Holdings (NYSE: CODI) between May 1, 2024, and May 7, 2025, both dates inclusive (the “Class Period”), of the important July 8, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Compass securities you may be entitled to compensation without payment of any out of pocket fees or costs through a ...